Aelis Farma: Availability of the 2023 Universal Registration Document
2024年4月26日 - 1:00AM
ビジネスワイヤ(英語)
Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a
clinical-stage biopharmaceutical company specialized in the
development of treatments for brain diseases, announces the
publication of its 2023 Universal Registration Document (URD)
approved by the French Financial Markets Authority (Autorité des
Marchés Financiers (AMF)) on April 24, 2024, under number
R.24-004.
The Universal Registration Document 2023 includes in
particular:
- The 2023 annual financial report;
- The statutory auditor’s reports;
- Information on the statutory auditor’s fees;
- Information relating to corporate social responsibility.
The URD can be consulted and downloaded on the Company’s website
under the heading Investors / Documentation, as well as on the AMF
website (https://www.amf-france.org).
Financial Agenda:
- Annual General Meeting, June 4, 2024
- 2024 Half-Year Results, September 16, 2024
***
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical
company that is developing a new class of drugs, the
Signaling-Specific inhibitors of the CB1 receptor of the
endocannabinoid system (CB1-SSi). CB1-SSi have been developed by
Aelis Farma based on the discovery of a natural regulatory
mechanism of CB1 hyperactivity made by the team led by Dr. Pier
Vincenzo Piazza, the Company’s CEO, when he was the director of the
Neurocentre Magendie of the INSERM in Bordeaux. By mimicking this
natural mechanism, CB1-SSi appear to selectively inhibit the
disease-related activity of the CB1 receptor without disrupting its
normal physiological activity. CB1-SSi have consequently the
potential to provide new safe treatments for several brain
diseases.
Aelis Farma is currently developing two first-in-class
clinical-stage drug candidates: AEF0117 for the treatment of
cannabis use disorder (CUD), currently being tested in a phase 2b
study in the United States; and AEF0217 for cognitive disorders,
including those of Down Syndrome (Trisomy 21), currently in a phase
1/2 study in Spain in people with Down syndrome. The Company also
has a portfolio of new innovative CB1-SSi for the treatment of
other disorders associated with a dysregulation of the activity of
the CB1 receptor.
Aelis Farma draws on the talents of more than 25 highly
qualified employees.
For more information, visit www.aelisfarma.com and follow us on
LinkedIn and Twitter.
ISIN: FR0014007ZB4 Ticker: AELIS B Compartment
of Euronext Paris
Disclaimer
Forward-looking statements Some information contained in
this press release are forward-looking statements, not historical
data. These forward-looking statements are based on current
beliefs, expectations, and assumptions, including, but not limited
to, assumptions about Aelis Farma's current and future strategy and
the environment in which Aelis Farma operates. They involve known
and unknown risks, uncertainties, and other factors, which may
cause actual results, performance, or achievements, or industry
results or other events, to differ materially from those described
or implied by such forward-looking statements. These risks and
uncertainties include those set out and described in detail in
Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration
Document approved by the Autorité des Marchés Financiers on April
24, 2024, under number R.24-004.
These forward-looking statements are made only as of the date of
this press release and Aelis Farma expressly disclaims any
obligation or undertaking to release any updates or corrections to
the forward-looking statements included in this press release to
reflect any change in expectations or events, conditions, or
circumstances on which any such forward-looking statement is based.
Forward-looking information and statements are not guarantees of
future performance and are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond Aelis Farma's control. Actual results could differ
materially from those described in, or implied or projected by,
forward-looking information and statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425488666/en/
AELIS FARMA Arsène Guekam Chief Corporate Development
Officer contact@aelisfarma.com
NewCap Dusan Oresansky / Aurélie Manavarere Investor
Relations aelis@newcap.eu +33 1 44 71 94 92
NewCap Arthur Rouillé Media Relations aelis@newcap.eu +33
1 44 71 00 15
Aelis Farma (EU:AELIS)
過去 株価チャート
から 4 2024 まで 5 2024
Aelis Farma (EU:AELIS)
過去 株価チャート
から 5 2023 まで 5 2024